J
Jianda Yuan
H指数:49
被引数:2.6万
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Pembrolizumab单药治疗与化疗在铂类预处理,复发或转移性鼻咽癌中的比较 (KEYNOTE-122): 一项开放标签,随机,III期试验
ANNALS OF ONCOLOGY
IF65.4
Immunotherapy biomarkers 2016: overcoming the barriers
免疫疗法生物标志物2016: 克服障碍
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients
外周CD8效应记忆1型T细胞与ipilimumab治疗的IV期黑色素瘤患者的预后相关
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma
淋巴细胞中的趋化因子受体模式反映了黑色素瘤的转移扩散
Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts)
肿瘤浸润淋巴细胞 (til) 和外周血的综合免疫学评估,以评估早期乳腺癌 (ESBC) 患者 (pts) 中冷冻消融 (cryo) 加伊匹单抗 (ipi) 的协同作用
CANCER RESEARCH
IF16.6
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (vol 25, pg 399, 2015)
CTLA-4阻断的抗癌免疫疗法: IL-2受体的强制性贡献和可溶性CD25的负面预后影响 (第25卷,399页,2015页)
CELL RESEARCH
IF25.9

